Evidence map›Paper›PMID 31599230›Full record

ArticleMedical science monitor : international medical journal of experimental and clinical research2019

The Effect of Ras Homolog C/Rho-Associated Coiled-Protein Kinase (Rho/ROCK) Signaling Pathways on Proliferation and Apoptosis of Human Myeloma Cells.

Xianqi Feng, Ling Zhang, Shumin Nie, Likun Zhuang, Wei Wang, Junxia Huang, Xueshen Yan, Fanjun Meng

Open access · hybridAbstract read
In one paragraph

Article in Medical science monitor : international medical journal of experimental and clinical research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.4field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Recent advances in targeted drug delivery systems for multiple myeloma.Journal of controlled release : official journal of the Controlled Release Society · 2024
    Review
  3. Targeting the Isoprenoid Biosynthetic Pathway in Multiple Myeloma.International journal of molecular sciences · 2022
    Review
  4. Hsa_circ_0041268 promotes NSCLC progress by sponging miR-214-5p/ROCK1.Journal of clinical laboratory analysis · 2022
    Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Xianqi FengDepartment of Hematology, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China (mainland).
Ling ZhangDepartment of Pediatrics, Laiwu People's Hospital, Laiwu, Shandong, China (mainland).
Shumin NieDepartment of Neurology, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China (mainland).
Likun ZhuangCentral Laboratory, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China (mainland).
Wei WangDepartment of Hematology, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China (mainland).
Junxia HuangDepartment of Hematology, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China (mainland).
Xueshen YanDepartment of Hematology, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China (mainland).
Fanjun MengDepartment of Hematology, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China (mainland).
Qingdao University · CNAffiliated Hospital of Qingdao University · CNJinan City People's Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND The aim of this study was to explore the impact of Ras homolog C/Rho-associated coiled-protein kinase (Rho/ROCK) signaling pathways intervention on biological characteristics of the human multiple myeloma cell lines RPMI-8226 and U266 cells, and to investigate the expression of RhoC, ROCK1, and ROCK2 in RPMI-8226 and U266 cells. MATERIAL AND METHODS RPMI8226 and U266 cell lines were treated by 5-aza-2-deoxycytidine (5-Aza-Dc), trichostatin A (TSA), RhoA inhibitor CCG-1423, Rac1 inhibitor NSC23766, and ROCK inhibitor fasudil. Cell proliferation was examined by Cell Counting Kit-8 (CCK-8) assay and clone formation. Cell apoptosis was examined by flow cytometry and TUNEL assay. The mRNA and protein expressions of RhoC, ROCK1, and ROCK2 were detected by quantitative reverse transcription-polymerase chain reaction (qRT-PCR) and western blot, respectively. RESULTS CCG-1423, NSC23766, and fasudil could significantly inhibit the proliferation of RPMI8226 and U266 cells. The inhibitory effect was dose- and time-dependent within a certain concentration range (P<0.05). After treatment with CCG-1423, NSC23766, and fasudil for 24 hours, the apoptosis rates of RPMI8226 and U266 cells were significantly higher than those of the control group, which were dose-dependent (P<0.05). Compared with the control group, the mRNA and protein expressions of RhoC, ROCK1, and ROCK2 in RPMI8226 and U266 cells were significantly decreased with single 5-Aza-Dc or TSA treatment. However, the effects were obviously stronger after combined treatment of 5-Aza-CdR and TSA (P<0.05). CONCLUSIONS We found that 5-Aza-Dc and TSA can effectively decrease the mRNA and protein expressions of RhoC, ROCK1, and ROCK2. Furthermore, Rho and ROCK inhibitors significantly inhibit cell growth and induce cell apoptosis in the human multiple myeloma cell lines RPMI-8226 and U266.

Indexed as

ApoptosisSignal Transduction1-(5-Isoquinolinesulfonyl)-2-MethylpiperazineAzacitidineCell Line, TumorCell ProliferationHumansHydroxamic AcidsMultiple MyelomaProtein Kinase Inhibitorsrho-Associated Kinasesrho GTP-Binding ProteinsRNA, Messenger1-(5-Isoquinolinesulfonyl)-2-MethylpiperazineAzacitidinefasudilHydroxamic AcidsProtein Kinase Inhibitorsrho-Associated Kinasesrho GTP-Binding ProteinsRNA, Messengertrichostatin A

Identifiers

PMID31599230
PMCPMC6798802
OpenAlexW2979392341

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.